Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.42 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29625190 | 1.00 | KMT2A (0.69) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL1901192 | 0.99 | KMT2A (0.70) | KMT2AEPHX2TLR2FABP7FABP5 | |
| Bromide SCHEMBL15809739 | 0.97 | KMT2A (0.69) | KMT2AEPHX2TLR2FABP7FABP5 | |
| Hydrochloric Acid SCHEMBL5158614 | 0.96 | KMT2A (0.71) | KMT2AEPHX2TLR2FABP7FABP5 | |
| Hydrochloric Acid SCHEMBL29377708 | 0.96 | KMT2A (0.71) | KMT2AEPHX2TLR2FABP7FABP5 | |
| Hydrochloric Acid SCHEMBL1929972 | 0.95 | KMT2A (0.73) | KMT2AEPHX2TLR2FABP7FABP5 | |
| Hydrochloric Acid SCHEMBL13858071 | 0.95 | KMT2A (0.73) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL5033236 | 0.95 | KMT2A (0.73) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL31135496 | 0.95 | KMT2A (0.73) | KMT2AEPHX2TLR2FABP7FABP5 | |
| Hydrochloric Acid SCHEMBL30681196 | 0.94 | KMT2A (0.62) | KMT2AEPHX2TLR2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304590-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2025-10-02 | — | — | US | disclosed |
| US-12371436-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2025-07-29 | — | — | US | disclosed |
| US-12296027-B2 | Molecular renal probes for detecting acute kidney injury | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-05-13 | — | — | US | disclosed |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | Enterprise Therapeutics Limited (GB) | 2024-07-16 | — | — | US | disclosed |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2024-02-29 | — | — | US | disclosed |
| US-11739094-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2023-08-29 | — | — | US | disclosed |
| EP-3794002-B1 | COMPOUNDS | ENTERPRISE THERAPEUTICS LTD (GB) | 2023-08-02 | — | — | EP | disclosed |
| CN-110214141-B | Benzodiazolium compounds as ENaC inhibitors | 企业治疗学有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20220096662-A1 | MOLECULAR RENAL PROBES FOR DETECTING ACUTE KIDNEY INJURY | Nanyang Technical University (SG) | 2022-03-31 | — | — | US | disclosed |
| US-20210188855-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2021-06-24 | — | — | US | disclosed |
| EP-3794002-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2021-03-24 | — | — | EP | disclosed |
| US-10941149-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2021-03-09 | — | — | US | disclosed |
| WO-2020159448-A1 | MOLECULAR RENAL PROBES FOR DETECTING ACUTE KIDNEY INJURY | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2020-08-06 | — | — | WO | disclosed |
| US-20190315757-A1 | BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2019-10-17 | — | — | US | disclosed |
| US-6897209-B2 | Labelled factor XIIIa substrates | GE HEALTHCARE LIMITED (GB) | 2005-05-24 | — | — | US | disclosed |
| EP-0994730-B1 | LABELLED FACTOR XIIIa SUBSTRATES | AMERSHAM PLC (GB) | 2005-05-04 | — | — | EP | disclosed |
| US-20040076580-A1 | Labelled factor XIIIa substrates | AMERSHAM PLC (GB) | 2004-04-22 | — | — | US | disclosed |
| US-6653299-B1 | Radiotagged complexes; thrombosis, embolism, atherosclerosis, inflammation, cancer | NYCOMED AMERSHAM PLC (GB) | 2003-11-25 | — | — | US | disclosed |
| EP-0994730-A2 | LABELLED FACTOR XIIIa SUBSTRATES | Nycomed Amersham PLC (GB) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998031399-A2 | LABELLED FACTOR XIIIa SUBSTRATES | NYCOMED AMERSHAM PLC (GB) | 1998-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739094-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | OPRD1 588/4885CA2 128/4885KMT2A 4337/4885 |
| US-20040076580-A1 | Labelled factor XIIIa substrates | F13B, F7, F9 | OPRD1 3267/4885CA2 2989/4885KMT2A 342/4885 |
| US-20190315757-A1 | BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS | NHERF1, SCNN1B, SCNN1A | OPRD1 609/4885CA2 147/4885KMT2A 4508/4885 |
| US-12371436-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | OPRD1 588/4885CA2 128/4885KMT2A 4337/4885 |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | SCNN1B, SCNN1A, SCNN1G | OPRD1 1039/4885CA2 156/4885KMT2A 4545/4885 |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | OPRD1 609/4885CA2 147/4885KMT2A 4508/4885 |
| US-20220096662-A1 | MOLECULAR RENAL PROBES FOR DETECTING ACUTE KIDNEY INJURY | ATP6V1B1, ANXA3, ZYX | OPRD1 1554/4885CA2 532/4885KMT2A 4014/4885 |
| US-12296027-B2 | Molecular renal probes for detecting acute kidney injury | ATP6V1B1, ANXA3, ZYX | OPRD1 1436/4885CA2 632/4885KMT2A 4213/4885 |
| US-20210188855-A1 | COMPOUNDS | NHERF1, SCNN1B, SCNN1A | OPRD1 1196/4885CA2 184/4885KMT2A 4270/4885 |
| US-10941149-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | OPRD1 588/4885CA2 128/4885KMT2A 4337/4885 |
| US-20250304590-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | OPRD1 609/4885CA2 147/4885KMT2A 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.